Literature DB >> 6274499

The management of brain metastases in germ cell tumors.

C J Logothetis, M L Samuels, A Trindade.   

Abstract

Twelve patients, with brain metastases from germ cell tumors were treated with combined whole brain irradiation and systemic chemotherapy. Two prognostic categories were identified. Patients with single brain metastases had a mean survival of 29.9 months, while patients with multiple brain lesions had a mean survival of 13.7 months. Four of the six patients with single brain lesions remain alive at 13, 14, 35 and 41 months following the clinical diagnosis of brain metastasis. The improved survival among patients with single lesions can be attributed to the sensitivity to chemotherapy of their tumors. Meningeal carcinomatosis, a previously unreported complication of metastatic germ cell tumor, developed in two patients who were initially treated for single brain metastasis. Both patients developed a clinical picture suggesting meningeal invasion by tumor and both had cytologic evidence in the cerebrospinal fluid of malignant cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6274499     DOI: 10.1002/1097-0142(19820101)49:1<12::aid-cncr2820490104>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Brain metastasis from non-seminomatous germ cell tumors of the testis: indications for aggressive treatment.

Authors:  Maurizio Salvati; Manolo Piccirilli; Antonino Raco; Antonino Santoro; Riccardo Frati; Jacopo Lenzi; Gaetano Lanzetta; Antonino Agrillo; Alessandro Frati
Journal:  Neurosurg Rev       Date:  2005-11-23       Impact factor: 3.042

2.  Chemotherapy for non-seminomatous germ-cell tumours.

Authors:  P M Wilkinson
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

3.  Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases.

Authors:  E A Neuwelt; S A Dahlborg
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

4.  Metastatic testicular cancer and extragonadal germ cell tumor presenting with neurological symptoms.

Authors:  N Borge; S D Fosså; A E Stenwig
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

5.  An attempt to treat pediatric intracranial alphaFP and betaHCG secreting germ cell tumors with chemotherapy alone. SFOP experience with 18 cases. Société Française d'Oncologie Pédiatrique.

Authors:  M C Baranzelli; C Patte; E Bouffet; M Portas; F Mechinaud-Lacroix; E Sariban; H Roche; C Kalifa
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

Review 6.  Malignant germ cell tumors metastatic to the brain: a model for a curable neoplasm? The Freiburg experience and a review of the literature.

Authors:  Johannes Lutterbach; Uwe Spetzger; Susanne Bartelt; Axel Pagenstecher
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

7.  Gamma knife radiosurgery in brain metastases from testicular tumors.

Authors:  A Nicolato; A Ria; R Foroni; P Manno; F Alessandrini; T Sava; F Lupidi; P Leone; S Maluta; G L Cetto; M Gerosa
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

8.  Central nervous system as sanctuary site of relapse in patients treated with chemotherapy for metastatic testicular cancer.

Authors:  A Gerl; C Clemm; P Kohl; A Schalhorn; W Wilmanns
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

9.  Management of brain metastases from breast cancer by combination chemotherapy.

Authors:  D Rosner; T Nemoto; J Pickren; W Lane
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

10.  Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.

Authors:  Robert J Morgan; Timothy Synold; Adam Mamelak; Dean Lim; Zaid Al-Kadhimi; Przemyslaw Twardowski; Lucille Leong; Warren Chow; Kim Margolin; Stephen Shibata; George Somlo; Yun Yen; Paul Frankel; James H Doroshow
Journal:  Cancer Chemother Pharmacol       Date:  2010-01-28       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.